How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

894 results for

Common Clotting Pathway

Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

42. Chronic Pelvic Pain

and sexual symptoms with common illnesses. Eur Urol, 2007. 52: 407. 257. Davis, S.N., et al. Is a sexual dysfunction domain important for quality of life in men with urological chronic pelvic pain syndrome? Signs "UPOINT" to yes. J Urol, 2013. 189: 146. 258. Cleeland, C.S. The Brief Pain Inventory User Guide. 2009. 259. Turk, D.C., et al. Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain, 2003. 106: 337. 260. Bullock, A.D., et al. Experimental autoimmune cystitis

2019 European Association of Urology

43. Critical Issues in the Evaluation and Management of Adult Patients Presenting to the Emergency Department With Acute Headache

70 Headache is a common and often a potentially high-risk complaint seen by the emergency physician. A 71 query of the National Hospital Ambulatory Medical Care Survey for 2015 found that nontraumatic headache was 72 identified as the fifth leading reason for emergency department (ED) visits, accounting for 3.8 million visits per 73 year (2.8 % of all ED visits). 1 This prevalence affects not only ED volumes but also resource utilization. Previous 74 studies have shown that up to 14% of patients (...) included January 1, 2007, to the search date of July 3, 2017. 519 520 521 Study Selection: Five hundred ninety-four articles were identified in the searches. Fifteen articles were 522 selected for further review, with zero Class I studies, 1 Class II study, and 1 Class III study included for this critical 523 question. 524 525 Headache is a common presenting complaint in ED visits. For patients who have not had head trauma, the 526 emergency physician is frequently trying to rule out the diagnosis

2019 American College of Emergency Physicians

44. Registries for Evaluating Patient Outcomes: A User's Guide: Fourth Edition (Draft)

not only on the product's dissolving the clot but also on the timeliness of its delivery. 35, 36 When defining patient outcomes, as well as other data elements, registries are advised to consider using existing core or minimum sets of outcome measures and common data elements whenever possible. Core or minimum sets of outcome measures specify and define the critical outcomes of interest in a disease or condition area; these recommendations generally are developed through consensus-based processes (...) References for Chapter 6 130 Chapter 7. Principles of Registry Ethics, Data Ownership, and Privacy 133 1. Introduction 133 2. Ethical Concerns Relating to Health Information Registries 141 2.1. Application of Ethical Principles 141 2.2. Transformation of Ethical Concerns Into Legal Requirements 145 2.2.1. The Common Rule 145 2.2.2. The Privacy Rule 147 2.2.3. FDA Regulations 151 2.2.4. Applicability of Regulations to Research; Multiple-Purpose Registries 152 3. Applicable Regulations 154 3.1. Public

2019 Effective Health Care Program (AHRQ)

45. AIM Clinical Appropriateness Guidelines for Pharmacogenetic Testing and Genetic Testing for Thrombotic Disorders

medication selection, dosage, and risk of adverse side effects. It also addresses genetic testing to predict risk of thrombosis. All tests listed in these guidelines may not require prior authorization; please refer to the health plan. Appropriate Use Criteria Pharmacogenetic Testing Pharmacogenetic testing of common variants associated with drug metabolism is medically necessary when either of the following criteria is met: • All of the following: - The individual is a candidate for a targeted drug (...) genotyping assays in which each included target does not meet the above criteria are not medically necessary. Thrombophilia Testing Testing for common variants in Factor V Leiden (F5) and prothrombin (F2) is medically necessary for any of the following indications: • Pregnant woman who has a personal history of an unprovoked venous thromboembolism (VTE) (e.g. not associated with fracture, surgery, prolonged immobilization, cancer) • In an individual with an unprovoked VTE when test results will impact

2019 AIM Specialty Health

46. Urological Trauma

from injury is twice as common in males, especially in relation to motor vehicle accidents (MVAs) and interpersonal violence. Trauma is therefore a serious public health problem with significant social and economic costs. Significant variation exists in the causes and the effects of traumatic injuries between geographical areas, and between low, middle, and high-income countries. It should be noted that alcohol and drug abuse increase the rate of traumatic injuries by precipitating interpersonal

2019 European Association of Urology

48. BSG consensus guidelines on the management of inflammatory bowel disease in adults

therapy 107 Other treatment 108 5 Common Disease Considerations 109 5.1 Infectious diseases and IBD: differential and concurrent diagnoses 109 5.1.1 Tuberculosis 109 5.1.2 Enteric infections associated with IBD 109 5.1.3 Clostridium difficile infection associated with IBD 110 5.1.4 Cytomegalovirus infection in IBD 111 Treatment of CMV in IBD 112 5.2 Immunosuppressive therapy 112 5.2.1 Prevention of infection related to IBD and immunosuppressive therapy 113 Epstein Barr Virus (...) Health Service (NHS) infrastructure and funding pathways. Accepted manuscript 16 Version accepted by Gut 10 th June 2019 2 Methodology The guideline is of relevance to adults aged 16 years and over and was developed according to Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology,[2] in accordance with the principles of the AGREE II tool,[3] and in compliance with the BSG Guidelines Advice Document.[4] The completed document was formally peer reviewed by the BSG

2019 British Society of Gastroenterology

49. Suspected Upper-Extremity Deep Vein Thrombosis.

such as an indwelling catheter, trauma, or extrinsic compression. Additionally, UEDVT involving the axillary vein or any more central vessel can be further described as proximal, with distal UEDVT affecting the brachial, radial, and ulnar veins. Secondary DVT of the upper extremity is by far the most common type. Indwelling venous devices such as catheters, pacemakers, and defibrillators put patients at the highest risk of thrombus [1,3-8]. Central venous catheters, which are difficult to place, such as those (...) to be at increased risk of UEDVT [14]. Although many of the same risk factors for lower-extremity DVT also increase the risk for UEDVT, research is helping to elucidate certain variables unique to thrombi in the upper extremity [1,15]. Primary UEDVT is less common and is diagnosed in about one-third of all UEDVT cases. Etiologies of primary UEDVT include thoracic outlet syndrome and effort-related thrombosis (Paget-Schroetter syndrome), and occasionally it is idiopathic. Patients who develop UEDVT often present

2019 American College of Radiology

50. Transjugular Intrahepatic Portosystemic Stent-Shunt (TIPSS) in the management of portal hypertension

provision in the UK 55 Personnel 55 Pathways and Protocols 56 M&M and Audit 56 Benchmarking 57 Research recommendations: 58 Conflicts of interest 60 Acknowledgements 60 Planned review date 60 References 61 Figures 71 Guidelines development group Name Qualifications Position Role Dr David Patch MRCP Consultant Hepatologist Chair Senior author Dr Dhiraj Tripathi MD FRCP Consultant Hepatologist Co-author (all sections) BSG Liver Section Representative Professor Adrian Stanley MD FRCP Consultant (...) of complications, the following preparation/preparatory work is recommended: a. Specialised scans to look at the liver and surrounding vessels. b. Liver and kidney function tests. c. Tests of the blood’s ability to clot. d. Heart function tests. e. A nutrition/dietary assessment. f. Tests to judge the risk of a patient developing HE after the TIPSS procedure. It is also possible to modify the procedure to reduce the risks of developing HE following TIPSS by for instance reducing the diameter of stent. We

2019 British Society of Gastroenterology

51. Point of Care in General Haematology

with the TEG 5000 is that it requires manual pipetting. The TEG 6s cartridges are preloaded and contain 4 channels, each with a different reagent that measure clot formation, detect the presence of heparin, assess both intrinsic and extrinsic pathway and measure fibrinogen. Thromboelastography is not a substitute for conventional laboratory testing, such as INR, but it offers additional information and may guide blood transfusion at the POC (Michelson & Bhatt, ). The use of viscoelastic assays during major (...) . Table 1. Currently available point of care tests and the clinical utility/setting. POC test Clinical utility Common locations Examples of POCT devices FBC (with 3‐part differential and 5‐part differential) Trauma (David et al ; Tongtoyai et al , ; Beynon et al , ) Haematology patients Emergency department operating theatre, Haematology clinics, GP (Celenza & Skinner ; Beynon et al , ) Pentra 60 ( Horiba ), XN‐L450, XN‐L 550 ( Sysmex ) (Kapuya et al , ) PT/INR Trauma (Dionizovik‐Dimanovski et al

2019 British Committee for Standards in Haematology

52. Plitidepsin (Aplidin) - Multiple Myeloma

and clotting abnormalities. Approximately 20% of patients are symptom free and are diagnosed by chance (2). The most common criteria used in diagnosis of symptomatic MM are the presence of neoplastic plasma cells comprising greater than 10% of BM cells or presence of a plasmacytoma; paraprotein (M protein) in the serum and/or urine; and evidence of related organ or tissue impairment due to plasma cell disorder. A clinical staging system, developed by Durie and Salmon (3), is useful for predicting survival (...) name: plitidepsin Procedure No. EMEA/H/C/004354/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Assessment report EMA/249101/2018 Page 2/156 Administrative information Name of the medicinal product: Aplidin Applicant: Pharma Mar, S.A. Avenida De Los Reyes 1 POL. IND. La Mina 28770 Colmenar Viejo Madrid SPAIN Active substance: plitidepsin International Non-proprietary Name/Common Name: plitidepsin Pharmaco-therapeutic group (ATC

2018 European Medicines Agency - EPARs

53. Caplacizumab (Cablivi) - thrombotic thrombocytopenic purpura (aTTP)

interval C max _D maximum concentration dose corrected CSR Clinical Study Report CT computed tomography DSMB Data Safety Monitoring Board ECG Electrocardiogram EMA European Medicines Agency FVIII coagulation factor VIII FVIII:C FVIII clotting activity GCP Good Clinical Practice GP HCP Glycoprotein host cell proteins HV healthy volunteer IgG immunoglobulin G INR IPC international normalized ratio in-process control i.v. Intravenous ITT intent-to-treat kDa kiloDalton KM Kaplan-Meier LDH lactate (...) or condition Cablivi is indicated for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression. 2.1.2. Epidemiology Acquired TTP is a life-threatening, autoimmune blood clotting disorder manifested by microvascular occlusions and consequent thrombocytopenia, haemolytic anaemia, and organ ischemia. It is a rare disease with an incidence of 1.2 to 11 cases per million per year (Miller et al., 2004

2018 European Medicines Agency - EPARs

54. Guidelines for the Provision of Intensive Care Services

Facilities 21 2.2 The Critical Care Team: Staffing Numbers and Work Patterns 24 2.2.1 Consultants 24 2.2.2 Trainee Medical Staff 26 2.2.3 Nurse Staffing 29 2.2.4 Advanced Critical Care Practitioners 32 2.2.5 Physiotherapy 34 2.2.6 Pharmacy 36 2.2.7 Dietetics 39 2.2.8 Occupational Therapy 42 2.2.9 Speech and Language Therapy 45 2.2.10 Practitioner Psychologists 48 CHAPTER THREE: CRITICAL CARE SERVICES – PROCESS 51 3.1 Patient Pathway 52 3.1.1 Admission, Discharge and Handover 52 3.1.2 Critical Care (...) is an introduction which describes the service. Chapter Two describes in detail the structure of the service, including physical facilities and staffing. Chapter Three details the process of the service and focuses on the patient’s pathway. Chapter Four describes the activity of the Critical Care service, including aspects of disease management and prevention as well as specialised critical care. Chapter Five contains other additional key components of the service, ranging from operational delivery networks

2019 Intensive Care Society

55. Risk estimation and the prevention of cardiovascular disease

Risk estimation and the prevention of cardiovascular disease Risk estimation and the prevention of cardiovascular disease| 1 1 Introduction 1.1 THE NEED FOR A GUIDELINE Cardiovascular disease (CVD) is an umbrella term that describes a range of conditions caused by blood clots (thrombosis) or build up of fatty deposits inside an artery that cause the artery to harden and narrow (atherosclerosis). The main underlying causes of CVD are coronary heart disease (CHD), stroke, peripheral arterial disease (...) in the patient’s clinical notes the medicine prescribed and, when not following common practice, the reasons for the choice y take responsibility for prescribing the medicine and for overseeing the patient’ s care, including monitoring the effects of the medicine. Non-medical prescribers should ensure that they are familiar with the legislative framework and their own professional prescribing standards. Prior to any prescribing, the licensing status of a medication should be checked in the summary of product

2017 SIGN

56. Standards for post-concussion care from diagnosis to the interdisciplinary concussion clinic

Introduction and Background 8 Concussion Recovery Pattern and Pathway 11 Standards for High Quality Post-Concussion Services and Concussion Clinics 14 Methods 43 Conclusions 44 Tools and Resources 47 1. Post-Concussion Care Pathway 48 2. Concussion Symptom Management 53 3. Scopes of Practice 54 4. Providing Information to Patients and Families (Patient Education) 63 5. Information Clinic/Networks Should Be Able to Provide to Patients 76 6. Core Services/Functions 77 7. Referral Indicators 79 8. Concussion (...) people who have common medical problems and can provide comprehensive management of a health issue. This person provides continuing care to patients and coordinates referrals to other health care practitioners. This person is most often a physician (family physician, pediatrician or sports medicine physician); however, a PCP may also be a nurse practitioner. ONF Standards for Post- Concussion Care 6 Scope of practice: The services a regulated health care practitioner is permitted to perform

2017 CPG Infobase

57. Guidelines on autopsy practice: Sudden death with likely cardiac pathology

not be missed as a terminal event promoting cardiac dysfunction and dysrhythmias. Structural abnormalities of the conduction system ? Absence of part of the atrioventricular node ? Damage to the His bundle ? Inflammation (e.g. sarcoid) ? Cystic tumour of the atrioventricular node ? Wolfe-Parkinson-White syndrome and other aberrant pathways. Note: It is impractical to serial section the whole conduction system and diagnoses such as Wolfe-Parkinson-White syndrome are made clinically and electrophysiologically (...) disease. Pregnancy ? Ischaemic heart disease ? Congenital heart disease ? Cardiomyopathy ? Coronary artery dissection ? SADS. Note: This list is not exhaustive and all-encompassing, but highlights the common lesions to be considered. 5 Specific health and safety aspects Generally there are no specific infection hazards in this arena of cardiac tissue examination, beyond standard autopsy health and safety realities. However, it should be remembered that many patients have cardiac pacemakers, which may

2017 Royal College of Pathologists

58. Guidelines on autopsy practice: Autopsy in sickle cell disease and persons with sickle trait

, and several have gone to High Court litigation for resolution on causality. Thus the following guidelines represent current thinking and practice among the interested parties. No major organisational changes or cost implications have been identified that would hinder the implementation of the guidelines. However, as sepsis has to be considered in all sickle cell disease patients who die, there must be facilities in mortuaries to undertake routine blood cultures and organ cultures, and a pathway (...) The sickle gene is common in the UK population. Genotypically, there are three main types of sickle cell disease (SCD): the HbSS, HbSC & HbS-beta thalassaemia genotypes. HbSS is the most common. Currently, the birth rate for SCD is about 1 in 2000 births, with more than 15 000 patients living with SCD. Additionally, about 1% of all births have the HbAS genes, giving them sickle cell trait (SCT). 1,2,3 Demographically, these people are concentrated in and around metropolitan areas such as London

2017 Royal College of Pathologists

59. Management of Acute Myocardial Infarction in patients presenting with ST-segment elevation

. MI, even presenting as STEMI, also occurs in the absence of obstructive coronary artery disease (CAD) on angiography. This type of MI is termed ‘myocardial infarction with non-obstructive coronary arteries’ (MINOCA) and is discussed in Chapter 9 of this document. 2.2 Epidemiology of ST-segment elevation myocardial infarction Worldwide, ischaemic heart disease is the single most common cause of death and its frequency is increasing. However, in Europe, there has been an overall trend (...) , the incidence rate ranged from 43 to 144 per 100 000 per year. Similarly, the reported adjusted incidence rates from the USA decreased from 133 per 100 000 in 1999 to 50 per 100 000 in 2008, whereas the incidence of NSTEMI remained constant or increased slightly. There is a consistent pattern for STEMI to be relatively more common in younger than in older people, and more common in men than in women. , The mortality in STEMI patients is influenced by many factors, among them advanced age, Killip class, time

Full Text available with Trip Pro

2017 European Society of Cardiology

60. Diagnosis and Treatment of Peripheral Arterial Diseases

for Peripheral Arterial disease CAS Carotid artery stenting CCA Common carotid artery CEA Carotid endarterectomy CFA Common femoral artery CHA 2 DS 2 - VASc Congestive heart failure, Hypertension, Age ≥75 (2 points), Diabetes mellitus, Stroke or TIA (2 points), Vascular disease, Age 65–74 years, Sex category CHARISMA Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance CI Confidence interval CKD Chronic kidney disease CLEVER Claudication: exercise versus endoluminal (...) events). Each vascular territory affected by atherosclerosis can be considered as marker of CV risk. 3.1 Epidemiology The epidemiology of different patterns of PADs is presented in the . The current background information and detailed discussion of the data for the following section of these Guidelines can be found in . 3.2 Risk factors Although different localizations of PADs share common major risk factors for atherosclerosis, the impact of those and/or available evidence differ per arterial site

Full Text available with Trip Pro

2017 European Society of Cardiology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>